Mer­ck KGaA makes $600M bet to boost man­u­fac­tur­ing for vi­ral vec­tors

Mer­ck KGaA an­nounced Wednes­day that it is ac­quir­ing Mirus Bio, a start­up that de­vel­ops trans­fec­tion reagents for vi­ral cell and gene ther­a­pies, for $600 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER